| Objective:The aim of the study was to examine the cost effectiveness of interferonβ-1α and interferon β-1b in the treatment of patients with relapsing remitting multiple sclerosis using Markov model and choose a relatively optimal treatment plan for RRMS.Methods:Heath states was divided based on the disability progression of RRMS and Expanded Disability status scale(EDSS).Transition probabilities for disease progression and utilities were obtained from the literature.Costs in the model were mainly obtained from drug price. Markov model of the two drugs was established using Markov model analytic method.Roll back analysis and Markov cohort simulation were conducted to compare the cost and effectiveness of the two drugs in the treatment of RRMS and obtain the optimal treatment plan.Results:Markov model analysis results:Interferonβ-1α has shown the best efficacy results in the treatment for relapsing remitting multiple sclerosis during a period 10 years.The cost and effectiveness of interferonβ-1α in the treatment of patients with relapsing remitting multiple sclerosis were 169130.846$ and 7.927 QALYs and the cost and effectiveness of interferonβ-1b for the treatment of relapsing remitting multiple sclerosis were 212572.623$ and 7.912 QALYs. The cost-effectiveness ratio of interferonβ-1α andinterferon β-1b were 21336.047$/QALY and 26867.116$/QALY.According to the cost-effectiveness ratio of the two drugs,interferonβ-1α was the better treatment.According to the sensitivity analysis, the change of the costs and utilities in the set range did non affect the model results.Conclusion:The present study suggested that the cost-effectiveness ratio of interferonβ-1α in the treatment of patients with RRMS was less than that of interferonβ-1b.Compared to interferonβ-1b,choosing interferonβ-1α as the therapeutic schedule of RRMS may obtain the biggest economic benefit from economic perspective. |
PDF Full Text Request